In a report released today, Marianne Bulot from Bank of America Securities reiterated a Hold rating on Fresenius Medical Care AG & Co. KGaA (0H9X – Research Report), with a price target of €48.00.
Marianne Bulot’s rating is based on the company’s recent performance and future outlook. Fresenius Medical Care AG & Co. KGaA exceeded expectations in the third quarter with a 5% increase in sales and a 2% rise in EBIT, driven by positive pricing and volume trends in Care Enablement and stable treatment volumes in the US. The company’s 2025 guidance aligns with market expectations, forecasting positive revenue growth and significant EBIT growth, with an improved EBIT margin forecast of 11-12%.
Despite these positive indicators, the guidance suggests limited changes to consensus, and there are concerns about potential pressures in the first quarter due to a strong flu season. Additionally, there is a lack of reiteration of post-2025 growth guidance, which could be a point of concern. The focus remains on cash allocation and growth drivers for 2025, indicating a cautious but optimistic outlook, justifying the Hold rating.
According to TipRanks, Bulot is an analyst with an average return of -22.8% and a 0.00% success rate.
In another report released today, Warburg Research also maintained a Hold rating on the stock with a €43.00 price target.